ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 128 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,361 | -67.9% | 48,328 | -54.5% | 0.00% | – |
| Q2 2023 | $147,494 | +71.6% | 106,111 | +96.3% | 0.00% | – |
| Q1 2023 | $85,969 | -46.0% | 54,068 | +111.6% | 0.00% | – |
| Q4 2022 | $159,222 | -20.4% | 25,557 | -14.5% | 0.00% | – |
| Q3 2022 | $200,000 | +5.3% | 29,881 | -0.0% | 0.00% | – |
| Q2 2022 | $190,000 | -18.8% | 29,888 | -40.8% | 0.00% | – |
| Q1 2022 | $234,000 | +136.4% | 50,521 | +154.7% | 0.00% | – |
| Q4 2021 | $99,000 | -58.6% | 19,835 | -0.2% | 0.00% | – |
| Q3 2021 | $239,000 | -29.1% | 19,874 | +24.7% | 0.00% | -100.0% |
| Q2 2021 | $337,000 | -54.7% | 15,938 | -39.9% | 0.00% | 0.0% |
| Q1 2021 | $744,000 | +13.2% | 26,519 | +5.1% | 0.00% | 0.0% |
| Q4 2020 | $657,000 | -51.9% | 25,241 | -31.3% | 0.00% | -66.7% |
| Q3 2020 | $1,365,000 | -29.3% | 36,734 | -2.4% | 0.00% | -25.0% |
| Q2 2020 | $1,931,000 | +91.4% | 37,643 | +17.3% | 0.00% | +33.3% |
| Q1 2020 | $1,009,000 | -52.5% | 32,095 | -9.8% | 0.00% | -25.0% |
| Q4 2019 | $2,124,000 | +101.7% | 35,598 | +24.1% | 0.00% | +33.3% |
| Q3 2019 | $1,053,000 | -9.3% | 28,687 | +14.5% | 0.00% | 0.0% |
| Q2 2019 | $1,161,000 | +32.2% | 25,057 | +14.1% | 0.00% | +50.0% |
| Q1 2019 | $878,000 | -13.6% | 21,967 | +0.2% | 0.00% | -33.3% |
| Q4 2018 | $1,016,000 | +5.2% | 21,927 | +0.4% | 0.00% | 0.0% |
| Q3 2018 | $966,000 | +62.9% | 21,838 | +45.1% | 0.00% | +50.0% |
| Q2 2018 | $593,000 | -33.7% | 15,053 | +21.0% | 0.00% | -33.3% |
| Q1 2018 | $895,000 | +27.5% | 12,441 | +16.7% | 0.00% | +50.0% |
| Q4 2017 | $702,000 | +53.9% | 10,659 | +17.2% | 0.00% | 0.0% |
| Q3 2017 | $456,000 | -20.4% | 9,092 | -26.9% | 0.00% | 0.0% |
| Q2 2017 | $573,000 | -4.7% | 12,434 | -26.4% | 0.00% | 0.0% |
| Q1 2017 | $601,000 | +103.0% | 16,883 | -22.0% | 0.00% | +100.0% |
| Q3 2016 | $296,000 | +100.0% | 21,643 | +44.1% | 0.00% | 0.0% |
| Q2 2016 | $148,000 | -35.4% | 15,017 | +10.6% | 0.00% | 0.0% |
| Q1 2016 | $229,000 | -31.8% | 13,579 | -10.5% | 0.00% | -50.0% |
| Q4 2015 | $336,000 | -37.5% | 15,173 | -33.0% | 0.00% | -33.3% |
| Q3 2015 | $538,000 | -93.1% | 22,653 | -76.4% | 0.00% | -85.7% |
| Q2 2015 | $7,836,000 | +225.1% | 95,796 | +268.6% | 0.02% | +61.5% |
| Q1 2015 | $2,410,000 | +122.7% | 25,992 | -3.2% | 0.01% | +116.7% |
| Q4 2014 | $1,082,000 | +150.5% | 26,850 | +52.1% | 0.01% | +50.0% |
| Q3 2014 | $432,000 | +64.3% | 17,650 | +6.5% | 0.00% | +100.0% |
| Q2 2014 | $263,000 | +11.4% | 16,575 | +6.1% | 0.00% | 0.0% |
| Q1 2014 | $236,000 | – | 15,625 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,679,835 | $69,675,000 | 19.39% |
| Endurant Capital Management LP | 207,293 | $5,390,000 | 1.94% |
| Bellevue Group AG | 5,138,451 | $133,599,000 | 1.53% |
| Rhenman & Partners Asset Management AB | 592,225 | $15,398,000 | 1.26% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,562,869 | $40,635,000 | 0.93% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 31,434 | $817,000 | 0.62% |
| WASATCH ADVISORS LP | 3,998,010 | $103,949,000 | 0.51% |
| HAMILTON LANE ADVISORS LLC | 46,181 | $1,201,000 | 0.45% |
| Boxer Capital, LLC | 500,000 | $13,000,000 | 0.42% |
| DCF Advisers, LLC | 38,500 | $1,001,000 | 0.41% |